Xencor, Inc. Share Price
NASDAQ: XNCR | Small CapXencor, Inc. Stock Performance
Open $20.43 | Prev. Close $19.97 | Circuit Range N/A |
Day Range $19.93 - $21.04 | Year Range $6.92 - $21.76 | Volume 58,880 |
Average Traded $20.75 |
Xencor, Inc. Share Price Today
As of 10 August 2026, Xencor, Inc.'s share price is $20.77. The stock opened at $20.43, compared to its previous close of $19.97. During today's trading session, Xencor, Inc.'s share price traded between $19.93 and $21.04, with an average price of $20.48. Over the past 52 weeks, the stock has recorded a high of $21.76 and a low of $6.92. In terms of performance, Xencor, Inc.'s share price has risen by 62.39% over the last six months and is up 155.63% on a year-on-year basis.
Xencor, Inc. Share Price Chart
Xencor, Inc. Stock Fundamentals & Key Indicators
Market Cap $1.54B | PE Ratio (TTM) -16.75 | Dividend Yield N/A |
EPS (TTM) $-1.24 | Revenue (TTM) $125.58M | Return On Equity (TTM) -14.50% |
Profit Margin -73.37% | Debt to Equity 0.15 | Quarterly Earnings Growth YoY 86.98% |
Xencor, Inc. Quarterly Profit & Loss
All figures in USD
Xencor, Inc. Annual Profit & Loss
All figures in USD
About Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Xencor, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $20.24 | $20.77 | +2.62% |
Jul 2026 | $15.97 | $20.24 | +25.56% |
Jun 2026 | $11.79 | $16.12 | +35.80% |
May 2026 | $11.84 | $11.87 | -0.46% |
Apr 2026 | $12.31 | $11.93 | -0.87% |
Mar 2026 | $12.45 | $12.03 | -5.94% |
Feb 2026 | $12.22 | $12.79 | +5.88% |
Jan 2026 | $15.24 | $12.08 | -21.05% |
Dec 2025 | $17.00 | $15.30 | -11.56% |
Nov 2025 | $14.49 | $17.30 | +17.69% |
Oct 2025 | $11.59 | $14.70 | +25.43% |
Sep 2025 | $8.29 | $11.72 | +44.25% |
XNCR Share Price FAQs
What is Xencor, Inc. share price today?
What is the 52 week high and 52 week low of Xencor, Inc. stock?
What is XNCR's market capitalisation today?
What is XNCR's net income for the last quarter?
What is the 5 year returns of XNCR?
What is the high & low stock price of XNCR today?
Can I buy XNCR shares in India?